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“Problems that remain persistently insoluble should always be suspected as questions asked 
in the wrong way.” 
–– Alan W. Watss 
 
  
  
  
ABSTRACT 
Attention-deficit/hyperactivity disorder (ADHD) is a highly prevalent and clinically 
heterogeneous neurodevelopmental disorder affecting approximately 3.4–7.3% children and 
adolescents and 2.5–3.4% adults worldwide, leading to adverse consequences for affected 
individuals, their families, and society at large. Despite the growing body of research, the 
etiology of ADHD remains obscure. Epidemiologic research is crucial for detecting disease 
risk factors. However, prior studies have rarely moved beyond identifying associations 
between proposed risk factors and later outcomes to rigorously testing the causality of these 
associations. The stagnation is partly due to the intrinsic limitations of observational studies, 
such as insufficient adjustment for genetic confounding. Large register-based data enable 
researchers to incorporate classical epidemiologic designs into genetically informative 
samples. Such genetically informative study designs are useful tools for unraveling the role of 
genetic and environmental factors in the development of diseases. In this thesis, the four 
studies used genetically informative designs to enhance the current understanding of the 
etiology of ADHD and the mechanisms underlying the associations between ADHD and its 
adverse health outcomes, including high body mass index (BMI) and suicidal behavior. 
In Study I, we attempted to quantify the familial aggregation of ADHD in a large 
representative Swedish family sample, consisting of siblings and cousins of varying degrees 
of genetic relatedness. The results demonstrated that the familial aggregation of ADHD 
generally increased with increasing genetic relatedness between family members. Persistence 
of ADHD into adulthood in family members was associated with higher degree of the 
familial aggregation compared to remission of ADHD prior to adulthood. 
In Study II, we assessed the co-aggregation of ADHD and overweight/obesity within families 
and further tested the hypothesis that the familial co-aggregation of the two conditions is at 
least in part due to common familial causes. The findings suggested an etiological overlap 
between ADHD and overweight/obesity. 
In Study III, we investigated the association between high maternal pre-pregnancy BMI and 
offspring ADHD both at the population level and within siblings. The findings indicated the 
contribution of shared familial factors to the association, which supported the conclusion 
from Study II. A direct causal effect of high maternal pre-pregnancy BMI on offspring 
ADHD was, however, not evident. 
In Study IV we examined the association between the use of ADHD medication and 
concomitant suicidal behavior. When the same individual was compared with him of herself 
for the rate of suicide-related events during on- and off-treatment periods, the results did not 
support that the use of ADHD medication increased the risk of concomitant suicidal behavior. 
In conclusion, observational studies using genetically informative designs may provide 
valuable insights into the etiology of ADHD. The familial aggregation of ADHD increases 
with increasing genetic relatedness. ADHD and overweight/obesity share etiological factors. 
In family settings, such shared etiological factors lead to the familial co-aggregation of the 
two conditions. Moreover, the shared etiological factors manifest as unmeasured familial 
confounding, which may partly account for the population-level association between high 
maternal pre-pregnancy BMI and offspring ADHD. The use of ADHD medication does not 
appear to increase the risk of concomitant suicidal behavior. Genetically informative designs 
should be increasingly used in future epidemiologic research to efficiently control for 
confounding and strengthen causal inferences. 
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1 INTRODUCTION 
Attention-deficit/hyperactivity disorder (ADHD) or hyperkinetic disorder (HKD) is a 
common neurodevelopmental disorder characterized by developmentally inappropriate levels 
of inattentive and/or hyperactive-impulsive symptoms that are manifested in multiple 
settings.1 The core symptoms of ADHD have early onset in childhood and may persist into 
adulthood in a substantial proportion of affected individuals.2 ADHD is associated with 
impairments in social, academic, and occupational functioning, leading to adverse 
consequences for affected individuals, their families, and society at large.3 Despite the 
growing body of research, the etiology of ADHD remains obscure. 
Large register-based data enable methodological innovations such as genetically informative 
designs. Such study designs, incorporating classical epidemiologic designs into genetically 
informative samples, are useful tools for investigating the role of genetic and environmental 
factors in the development of diseases. Demonstrating familial aggregation of a disease often 
serves as a crucial first step leading towards further identification of disease risk factors 
shared by family members. A comprehensive evaluation of the familial aggregation of 
ADHD in a representative Swedish sample with prospective follow-up is therefore warranted. 
Assessing familial co-aggregation of diseases may uncover the etiological overlaps between 
these diseases. For instance, if ADHD and high body mass index (BMI) indeed share 
etiological underpinnings, a clearer understanding of either one of the two conditions may 
be implicated in the preventive, diagnostic, therapeutic processes of both. 
Many observational studies cannot move beyond identifying associations between proposed 
risk factors and diseases to rigorously testing the causality of these associations. Such 
stagnation is partly due to the intrinsic limitation of observational studies with respect to 
adjustment for unmeasured confounders. A potential association between high maternal pre-
pregnancy BMI and offspring ADHD has been proposed, but the role of familial confounding 
in the association needs to be clarified before any causal claim can be made. Likewise, 
pharmacoepidemiologic studies of the association between the use of ADHD medication and 
suicidal behavior may be confounded by ADHD per se being associated with suicidal 
behavior via genetic overlap. Genetically informative designs (e.g. sibling comparison and 
within-individual comparison) can be used to efficiently control for certain types of 
unmeasured confounders, including, but not limited to, genetic background, and therefore 
may help address the causal nature of the aforementioned associations. 
This thesis seeks to illustrate the applicability of genetically informative designs in 
observational studies that aim to advance the understanding of the etiology of ADHD and the 
mechanisms underlying the associations between ADHD and its adverse health outcomes. 
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2 BACKGROUND 
2.1 ATTENTION-DEFICIT/HYPERACTIVITY DISORDER (ADHD) 
2.1.1 Early history 
Despite the ongoing debate over whether ADHD is a valid diagnosis, the ADHD-like 
syndrome is not a contemporary phenomenon. The earliest medical literature on ADHD dates 
back to 1775 when the German physician, Melchior Adam Weikard, first described a series 
of inattentive symptoms in a German textbook.4 This was 33 years before the term 
"psychiatry" was first coined in human history. In 1789, similar inattentive symptoms caught 
the attention of a Scottish physician, Sir Alexander Crichton, whose written account denotes 
“mental restlessness”.5 Surprisingly, his description of the symptoms, though not fully 
meeting the criteria for a clinical diagnosis, was found to be almost entirely consistent with 
the symptoms of the inattentive subtype of ADHD in the Diagnostic Statistical Manual of 
Mental Disorders, Fourth Edition, Text Revision (DSM-IV-TR)6 released two centuries 
later. 
2.1.2 Clinical Diagnosis 
Two classification systems have been used in parallel for the diagnosis of ADHD/HDK: the 
DSM in the United States and the International Statistical Classification of Diseases and 
Related Health Problems (ICD) in Europe and other parts of the world. The DSM-IV allows 
for an ADHD diagnosis based on the presence of either inattentive or hyperactive/impulsive 
symptoms, together with impairments in social, academic, and/or occupational functioning 
caused by the symptoms.6 ICD-10 diagnostic criteria for HKD require the presence of both 
inattentive and hyperactive/impulsive symptoms across more than two settings (e.g. school 
and home).7 Compared with the DSM-IV, the ICD-10 is more restrictive and tends to capture 
individuals affected by more severe forms of the disorder.8 Since 2013, the DSM-5 has 
replaced the DSM-IV.9 Major changes in the DSM-5 diagnostic criteria for ADHD are as 
follows: (1) the age of onset is changed from before 7 years to before 12 years; (2) only five 
instead of six symptoms for each symptom domain are required for the diagnosis among 
individuals 17 years or older; and (3) ADHD is allowed to be diagnosed in conjunction with 
autism spectrum disorder.10,11 Apart from these major changes, the DSM-5 has retained the 
three categories of ADHD from the DSM-IV, which are now referred to as combined 
presentation, predominantly inattentive presentation, and predominantly hyperactive-
impulsive presentation.9 
2.1.3 Prevalence 
The worldwide prevalence of ADHD has been estimated to be 3.4–7.2% in children and 
adolescents.12,13 The large variation in the prevalence estimates results mainly from 
methodological heterogeneity across studies conducted in different geographic locations.14,15 
The most influential methodological factors include selection of diagnostic criteria, source of 
information, and requirement of functional impairment for a diagnosis to be made.14,15 In 
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recent years, the rate of clinical diagnosis of ADHD in children and adolescents is 
increasing,16 most likely owing to improved public awareness, more accessible health care, 
and changing clinical practices. However, there is no solid evidence supporting an increase in 
the real prevalence of ADHD over the past three decades.14 Despite common concerns about 
over-diagnosis of ADHD in children, systematic over-diagnosis is not evident.17 Although 
ADHD is over-represented among males in clinical settings, no sex difference in the 
prevalence of ADHD was found between non-referred males and females.18 Longitudinal 
studies have reported higher rates of age-dependent symptomatic decline for 
hyperactivity/impulsivity than for inattention.19,20 Approximately two-thirds of the patients 
cannot achieve full remission by adulthood and 15% of patients continue to meet full 
diagnostic criteria for ADHD.2 
The prevalence of adult ADHD has been estimated to be 2.5–3.4%.21,22 With the 
implementation of the DSM-5, it is likely that more adults will be diagnosed with ADHD.11,23 
Nevertheless, adults with ADHD remain largely under-diagnosed and untreated.24 Currently, 
a valid diagnosis of adult ADHD requires childhood-onset of ADHD symptoms.9 One cohort 
study, however, has shown that 90% of adult ADHD cases did not have childhood onset of 
symptoms, challenging the current diagnostic conventions.25 
2.1.4 Pathophysiology 
Neuropsychological functioning and neuroimaging research has revealed the neurobiological 
heterogeneity of ADHD. Deficits in multiple neurocognitive domains related to ADHD have 
been reliably identified. The most replicated findings point to executive functioning deficits, 
including deficits in working memory, response inhibition, vigilance, and planning.26 Studies 
of delay aversion have shown that patients with ADHD are inclined to prefer smaller 
immediate rewards to larger delayed ones.27,28 Deficits in other functioning domains, 
including reaction time variability,29 language and speech,30 and motor control,31 have also 
been linked to ADHD. While most patients with ADHD suffer from impairment in one or 
two, but rarely all, of these neurocognitive domains, some patients show no impairment in 
any domain. 
Neuroimaging studies have revealed possible associations between ADHD and multiple 
structural and functional brain abnormalities. Functional magnetic resonance imaging studies 
have highlighted that alterations in neural networks may be implicated in ADHD in both 
children and adults.32 Specifically, hypoactivity in the frontoparietal and ventral attentional 
networks and hyperactivity in the default, ventral attention, and somatomotor networks have 
been observed in pediatric patients, while hypoactivity in the frontoparietal system and 
hyperactivity in the visual, dorsal attention, and default networks have been found to be 
predominant in adult patients. Structural magnetic resonance imaging studies have linked 
changes in the basal ganglia and limbic regions to ADHD and indicated that these changes 
might become less obvious over time among individuals treated by ADHD medication.33 
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2.1.5 Risk factors 
ADHD is a multifactorial disorder influenced by the complex interplay between many genetic 
and environmental factors within their temporal context. To date, no biomarker has been 
identified for screening the risk of the disorder or facilitating the diagnostic procedure. 
Despite a lack of thorough understanding of the etiology, studies have shown that ADHD is 
better viewed as an extreme of a continuously varying quantitative trait in the population and 
the full range of ADHD symptoms seem to be affected by the same genetic and 
environmental factors.34 
2.1.5.1 Genetic factors 
Family studies have reported familial aggregation of ADHD in first- and second-degree 
relatives.35-38 Twin studies have estimated the relative genetic and environmental 
contributions to the phenotypic variance in ADHD in the population. The heritability of 
ADHD, i.e., the proportion of phenotypic variance in the quantitative trait or the liability of 
ADHD that is attributable to genetic variation in the population, is around 70-80%.39,40 This 
heritability estimate is almost as high as the estimate for schizophrenia.41 With the advent of 
genomic era, molecular genetic studies are beginning to reveal the complex genetic 
architecture underpinning the disorder. About 40% of the heritability can be attributed to 
common genetic variants, particularly single nucleotide polymorphisms (SNPs), of small 
individual effects.42 Although genome-wide association studies (GWASs) have failed to 
identify specific genome-wide significant loci associated with ADHD,43 meta-analyses of 
candidate gene studies have suggested associations between genetic variants involved in 
monoamine neurotransmitter system and ADHD.44 GWAS-based pathway and network 
analyses have linked ADHD to genes regulating the dopaminergic, serotonergic, and 
noradrenergic systems and neuritis outgrowth.45,46 Large rare copy number variants (CNVs) 
appear to play a role in the etiology of ADHD.47-49 These CNVs are also implicated in 
schizophrenia and autism.48 
In addition, common psychiatric disorders, including ADHD, are found to be influenced by a 
general genetic factor.50 Prior studies of familial co-aggregation of two disorders have 
indicated etiological overlaps of genetic origin between ADHD and other psychiatric 
conditions including schizophrenia,51 bipolar disorder,51 substance use disorder,52 and 
suicidal behavior.53 Much less is known about the relationship between ADHD and non-
psychiatric conditions such as obesity. 
2.1.5.2 Non-genetic factors 
Observational studies have linked ADHD to several putative non-genetic risk factors, 
including prenatal and perinatal conditions, toxins, dietary factors, and psychosocial 
adversities,54 with the causal nature of these factors being largely unknown. Family-based 
quasi-experimental studies (e.g. co-twin control, sibling- and cousin-comparison, and 
adoption studies) enable testing of the extent to which these associations are consistent with 
causal hypotheses.55 According to the findings from such genetically sensitive studies, several 
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observed associations between prenatal and perinatal factors (e.g. smoking during pregnancy 
and stress during pregnancy) and ADHD are better explained by unmeasured familial 
confounding.56-58 In contrast, low birth weight, advanced paternal age at childbearing, low 
family income, and severe psychosocial deprivation might be causal risk factors of ADHD.59-
62 
In recent years, maternal pre-pregnancy overweight/obesity has been proposed as risk factor 
for neurodevelopmental outcomes, including ADHD, in offspring later in life.63,64 These 
proposed associations are biologically plausible given the well-known fetal programming 
hypothesis, i.e., exposure to suboptimal intrauterine environment may alter physiological 
parameters during the development of embryo and such physiological alternations may 
result in long-term adverse effects on offspring development.65 Two epidemiologic studies 
have reported associations between pre-pregnancy overweight/obesity and teacher-rated 
ADHD symptoms among school-aged children.66,67 The findings were further supported by 
an animal study in a randomized experimental setting.68 However, considerable inter-species 
differences largely limited the generalizability of findings from animals to humans.69 
Drawing a causal conclusion based on the animal study would be premature, especially when 
the causal hypothesis has not yet been tested in family-based quasi-experimental studies. 
2.1.6 Adverse health outcomes 
ADHD has been associated with many detrimental health outcomes (e.g., substance use, 
sleeping problems, obesity and physical fitness, suicide, and premature mortality).70,71 The 
associations with obesity and suicide are two relevant themes in this thesis. 
2.1.6.1 Associations with obesity 
Obesity is defined as excessive fat accumulation in adipose tissue, leading to impaired 
health.72 The most commonly used measure for overweight and obesity is BMI. BMI is 
calculated as body weight in kilograms divided by height in meters squared, and categorized 
into under weight (BMI<18.5), normal weight (18.5≤BMI<25), overweight (25≤BMI<30), 
and obesity (BMI≥30) according to the criteria given by the World Health Organization 
(WHO).73 During the last few decades, many countries have documented an increase in the 
average BMI at the population level.74-76 The prevalence of obesity in adults is estimated to 
be more than 10% in Sweden75 and 34.9% in the United States.77 Given its adverse impact on 
health and quality of life, obesity imposes considerable economic burden to individuals and 
public health systems.78 Despite meta-analytic evidence for significant association between 
ADHD and obesity in children and adults,79 the underlying mechanisms are yet to be fully 
understood. 
Several plausible explanations might account for the association between ADHD and obesity. 
First, ADHD might directly cause obesity through the inattentive and impulsive 
components.80 For example, lack of self-awareness of food intake due to inattention and 
deficient inhibitory control may give rise to unhealthy eating behaviors, which may, in turn, 
lead to increased risk of obesity. Life style factors may serve as mediators of the association. 
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Studies have reported that children with ADHD tend to spend more time in watching 
television and engage in less physical activity compared with children without ADHD.81 
Second, ADHD and obesity may share common etiological factors. Reward deficiency, 
which results from dysfunction of dopaminergic system, and oxidative stress have been 
proposed as the neurobiological mechanisms underlying the etiology of ADHD and 
obesity.82,83 Moreover, ADHD and obesity are both highly heritable complex conditions 
39,40,84 and common pleiotropic genetic variants might regulate both traits.85 Third, individuals 
with obesity might have sleeping and breathing problems and thereby manifest ADHD-like 
symptoms.82 In this thesis, however, we assumed that ADHD diagnosis due to such 
symptomatic confusion was unlikely because the ascertainment of ADHD cases was 
primarily based on clinical diagnosis made by specialists in psychiatry rather than community 
surveys. 
2.1.6.2 Association with suicidal behavior 
Suicide is one of the leading causes of death worldwide. The estimated worldwide annual 
mortality is 11.4 per 100 000 population (15.0 for males and 8.0 for females).86 In most 
countries, males are more likely to commit suicide than females, whereas females attempt 
suicide more frequently than males.87 In recent years, suicide rates have been increasing 
among young men.88 Furthermore, it has been shown that suicide aggregates in families.89,90 
Convergent evidence from adoption, twin, and family studies consistently suggests a genetic 
contribution to suicidal behavior. The heritability of nonfatal suicide attempts varies between 
17% and 45%.91 Although rare in the general population, suicide rates are higher in 
individuals with psychiatric conditions, particularly mood disorder and substance use 
disorder.92 Growing evidence has shown that ADHD is associated with an increased risk of 
suicidal behavior.93-96 One Swedish population-based family study has found that ADHD and 
suicidal behavior shared etiological factors.53 The shared etiological factors might have roots 
in serotonergic system; for instance, low concentration of cerebrospinal fluid 5-
hydroxyindoleacetic acid has been implicated in impulsive suicidal behavior.97 
2.1.7 Treatment 
Comprehensive treatment of ADHD involves patient education, non-pharmacotherapy, and 
pharmacotherapy modalities.1 Education to patients with ADHD and their families may 
improve adherence to treatment and help optimize the effects of non-pharmacotherapy and 
pharmacotherapy.98 Cognitive behavioral therapy is the most commonly used non-
pharmacologic option for ADHD. It also constituted a key component of the Multimodal 
Treatment study of children with ADHD (MTA).99 From the MTA study, no obvious 
additional benefit from combining non-pharmacotherapy and pharmacotherapy over 
pharmacotherapy alone was observed in terms of core symptom reduction. However, the 
combination helped with the relief of secondary symptoms and the improvement of 
functioning. 
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Pharmacotherapy remains a cornerstone of ADHD treatment. According to the treatment 
recommendations from the Swedish Medical Products Agency, pharmacotherapy should be 
reserved for moderate to severe cases, or mild cases for which non-pharmacologic options 
have failed.100 In Sweden, registered medications for ADHD treatment include psycho-
stimulants (i.e., methylphenidate, amphetamine, and dexamphetamine) and the non-stimulant 
(i.e., atomoxetine). Both psycho-stimulants and atomoxetine have shown beneficial effects on 
the core symptoms of ADHD.101 Psycho-stimulants increase intra-synaptic dopamine and 
noradrenaline concentration.102 Methylphenidate is a pre-synaptic reuptake inhibitor of 
dopamine and noradrenaline and is recommended as first-line pharmacotherapy for 
ADHD,103 whereas amphetamine and dexamphetamine also increase the release of dopamine 
in the pre-synaptic neuron. Meta-analytic evidence supports the efficacy of stimulants for 
ADHD in both children and adults.104 Common adverse effects of stimulants include 
headache, decreased appetite and sleep disturbance.105 Small delays in growth may occur to 
some individuals, but these delays hardly influence ultimate height in adulthood.106 
Atomoxetine acts as a selective noradrenaline reuptake inhibitor. Since atomoxetine does 
not increase the risk for abuse and has generally lower risk of other side effects compared to 
stimulants, it is considered a safe option for the treatment of comorbid ADHD and 
substance abuse disorder.107 For patients with comorbid psychiatric conditions, particularly 
severe mood or substance use disorder, effective management of ADHD can be achieved 
after these comorbid conditions are treated first.108 
Suicide risk assessment is a critical part of psychiatric evaluation. Although suicide-related 
events rarely occur with pharmacotherapy of ADHD, cautions about suicidality are added to 
the information on product characteristic of methylphenidate and dexamphetamine.109 Based 
on 12 short-term, placebo-controlled clinical trials, the Food and Drug Administration (FDA) 
issued a black-box warning on atomoxetine due to a small but significantly increased risk of 
suicidal ideation in children and adolescents in 2005.110 A meta-analysis of 14 clinical trials 
also reported a statistically significant association between the use of atomoxetine and 
suicidal ideation.111 Small observational studies have shown that medicated ADHD patients 
had increased risk of suicidal behavior compared with the general population.112,113 In 
contrast, one study reported that boys treated with methylphenidate had decreased risk of 
suicide attempts later in young adulthood compared with those untreated.114 The rarity of 
suicide-related events (completed suicide or suicide attempts) in prior studies raised 
substantial uncertainty surrounding the results. It remains unclear whether the possible 
treatment-emergent suicidal ideation suggested by the clinical trials will diminish as the 
treatment proceeds or eventually develop into suicidal behavior. 
2.2 CAUSAL INFERENCE IN BRIEF 
Scientific knowledge can be viewed as a body of currently unrefuted hypotheses that seem to 
explain existing observations.115 Likewise, the goal of causal inference in epidemiologic 
research is not to provide conclusive evidence for causality, but to test whether a causal 
hypothesis can survive attempts at refutation, so as to narrow down the number of plausible 
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explanations for observable associations.116 In the following text, causal inference in 
randomized controlled trails (RCTs) and observational studies will be briefly discussed. 
2.2.1 Randomized controlled trials 
RCT is deemed to provide the highest level of evidence for causal inference in medical 
science.117 In RCT, eligible study participants are randomly assigned to intervention group 
and control group.118 Both groups are followed by a certain length of time. Through 
randomization, any systematic differences between the two groups at the baseline are 
balanced out given a large enough sample size. Significant between-group differences at the 
end of the follow-up can thereby be solely attributed to the intervention. Nevertheless, RCTs 
are not always feasible due to operational, ethical, or economical considerations.119 For 
instance, in research aiming at investigating whether pre-pregnancy obesity causes offspring 
ADHD, researchers cannot experimentally manipulate maternal BMI levels. Using RCTs to 
examine the occurrence of rare adverse events (e.g. suicide attempts) potentially related to an 
intervention would be very expensive due to the required large sample and long follow-up. 
Participants failing to comply with their allocated treatment (i.e., non-compliance) may 
induce systematic differences between groups that were not there at baseline.120 Lack of 
external validity is another limitation of RCTs, as the eligible participants in RCTs may not 
be representative of the target population owing to strict inclusion and exclusion criteria.121 
Some researchers have pointed out that RCTs are no more than good experimental designs 
under certain circumstances and the shortcomings of RCTs can make themselves inferior to 
many appropriately designed observational studies.122 
2.2.2 Observational studies 
In observational studies, researchers address the potential effect of an exposure on an 
outcome based on a study population or a sample randomly drawn from the target population, 
without exposure intervention. Although definitive evidence for the causality of the exposure-
outcome association is unattainable, findings from observational studies may have better real-
life applicability compared to findings from RCTs.122 In observational studies, an observed 
association between a putative risk factor X and an outcome Y in a population might be due 
to one or more of the following reasons: (1) X causes Y; (2) Y causes X (reverse causation); 
(3) X and Y share a common cause C (confounding effect); (4) random events.60 Studies 
using prospective longitudinal designs may rule out reverse causation, because an outcome 
cannot cause an exposure if the outcome is preceded by the exposure. Increasing sample size 
may reduce the influence of random events. However, insufficient adjustment for 
confounding is an intrinsic limitation of observational studies. 
Confounding leads to a lack of comparability between exposed and unexposed groups, which 
gives rise to a bias in the estimation of the causal effect of an exposure on an outcome.123 
Such lack of comparability can be caused jointly by a group of risk factors of the outcome, or 
confounders. A confounder refers to a cause or a proxy of a cause of the outcome, which is 
associated with, but not affected by, the exposure.115 For example, cigarette lighter users are 
 9 
more likely to develop lung cancer, but such empirical association is not causal, because it is 
confounded by smoking behavior. Obviously, smokers are over-represented among cigarette 
lighter users and smoking is the real causal risk factor of lung cancer. In other words, 
smoking, as a confounder, induces a confounding bias to the association between the use of 
cigarette lighter and lung cancer. 
 
In observational studies, confounding can be addressed through controlling for 
confounders.123 Reliably measured confounders can be handled through stratification or 
regression model adjustment. When confounders cannot be precisely measured (e.g. genetic 
Box 1. Directed acyclic graphs 
Directed acyclic graphs (DAGs) have long been used to visually present hypothetic 
relations between variables, which may facilitate the analytic process of identifying 
sources of bias and help with statistical adjustment. 
• An arrow between X and M means X may cause M, but not the other way around.  
• The lack of arrow from C to M means that C does not have a direct causal effect on 
M (however, C may have a mediated effect on M through X). 
• Variable M lies in the causal path way between X and Y and thus is a mediator of the 
causal effect of X on Y.  
• Variable C is the common cause of X and Y and is referred to as a confounder. When 
estimating the causal effect of X on Y, we should adjust for variable C.  
• Since two arrows point towards the same variable Z, Z is a collider and represents the 
common effect of X and Y. A spurious assotiation between X and Y may be induced 
by inappropriate adjustment for the collider Z, which is called collider bias or 
selection bias. When estimating the causal effect of X on Y, we should not adjust for 
variable Z. 
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background and childhood environment), genetically informative study designs may come 
into play. 
2.3 WHY ARE GENETICALLY INFORMATIVE DESIGNS NEEDED? 
Large register-based data and reliably identified family pedigrees enable researchers to 
incorporate classical epidemiologic study designs (e.g. cohort designs and case-control 
designs) into family samples or samples with measurements repeatedly taken from the same 
individuals in observational studies. Such genetically informative designs are superior to 
classical study designs with respect to elucidating the role of genetic and environmental 
factors in the development of diseases. There is a critical need for genetically informative 
designs in observational studies for several reasons. 
First, they make important contribution to studies assessing familial aggregation and 
estimating familial risk of a specific disease. Demonstrating familial aggregation of a disease 
often serves as the first step leading towards further identification of genetic determinants of a 
disease. Under certain conditions, comparing the strength of the familial aggregation of a 
disease between subgroups of relatives (e.g. maternal and paternal half siblings) may shed 
new light on genetic and environmental contributions to the risk of the disease. Moreover, 
estimating familial risk of a disease by sex and disease feature may help identify target 
groups for diagnostic screening and enlighten counseling services. Due to limited access to 
representative family samples, prior studies have never comprehensively assessed familial 
aggregation of ADHD among family members who are of varying degrees of relatedness and 
nested in the sample population. A nation-wide study of the familial aggregation of ADHD, 
with special focus on the impacts of sex and persistence of ADHD into adulthood (Study I), 
is therefore warranted. 
Second, given large enough family sample, familial aggregation studies can be extended to 
familial co-aggregation of two diseases. Familial co-aggregation studies estimate familial risk 
of one disease among individuals with family history of another disease. Under plausible 
assumptions, researchers can test whether two diseases share etiological factors or they 
simply represent two distinct entities. Such studies are appealing because if an etiological 
overlap between two diseases is confirmed, advancing the understanding of one disease may 
benefit the preventive, diagnostic, and therapeutic processes of both. Study II was a familial 
co-aggregation study seeking evidence for an etiological overlap between two highly 
heritable conditions, ADHD and overweight/obesity. 
Third, the application of genetically informative designs may shift the field of developmental 
epidemiology from documenting putative associations to systematically testing rival causal 
hypotheses. Studies using genetically informative designs (e.g. sibling and cousin 
comparisons) can handle unmeasured familial confounding by design features and measured 
confounding in the same way as traditional epidemiologic research. Accordingly, these 
studies may provide more stringent causality tests. In Study III, we revisited the association 
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between high maternal pre-pregnancy BMI and offspring ADHD using a sibling-comparison 
design. 
Last but not least, within-individual comparison design, as a special case of genetically 
informative designs, can make pharmacoepidemiologic studies less prone to confounding by 
indication (i.e., indication for treatment is associated with the risk of outcome under study) in 
the investigation of drug safety issues. In Study IV, we investigated the association between 
the use of ADHD medication and concomitant suicidal behavior using a within-individual 
comparison design to account for the potential confounding by indication due to the fact that 
ADHD per se is associated with suicidal behavior.93-96 
The rationales behind the genetically informative designs used in this thesis will be further 
discussed in Section 5.1. 
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3 AIMS 
The overarching aim of this thesis was to enhance the current understanding of the etiology of 
ADHD and the mechanisms underlying the associations between ADHD and its adverse 
health outcomes by using genetically informative study designs. 
The specific aims of each study were: 
I. To comprehensively and precisely evaluate the familial aggregation of ADHD 
among relatives of varying degrees of genetic relatedness and to examine the 
influences of sex and persistence of ADHD into adulthood on the familial 
aggregation (Study I) 
 
II. To assess the familial co-aggregation of ADHD and overweight/obeisty in 
siblings and cousins and to test the hypothesis that ADHD and overweight/obesity 
share etiological factors (Study II) 
 
III. To examine whether the association between high maternal pre-pregnancy BMI 
and offspring ADHD is consistent with a causal hypothesis or better explained by 
familial confounding (Study III) 
 
IV. To investigate whether the use of ADHD medication can increase the risk of 
concomitant suicidal behavior (Study IV) 
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4 DATA SOURCES 
4.1 SWEDISH REGISTERS 
Every resident in Sweden has been assigned a ten-digit personal identity number (PIN) since 
1947.124 The PIN serves as a unique identifier for public administration and enables 
unambiguous linkage between national registers, which forms the basis of register-based 
medical research in Sweden. 
The Total Population Register (TPR) was established by Statistics Sweden in 1968.125 The 
register contains information on sex, date and place of birth, date of death, date of migration, 
civil status, and many other variables for Swedish residents who were born since 1932 and 
being alive in 1968. 
The Multi-Generation Register (MGR) is part of the TPR and links individuals in the TPR 
(index persons) to their biological and adoptive parents.126,127 Index persons (i.e., individuals 
through whom family relationships are ascertained) are limited to those born since 1932 and 
those alive on January 1, 1961. Linkages between index persons and their parents are missing 
if the parents were no longer alive in 1947 when PIN was initially introduced. The register 
has nearly complete coverage for index persons born in Sweden since 1947, among whom 
97% can be linked to their biological mothers and 95% to their biological fathers. In 
immigrant families, such linkages are possible only if the immigrations took place before the 
index persons turned 18. The register enables identification of family relatives of varying 
degrees of relatedness. In Studies I-III, the register was used to identify siblings and cousins. 
The Medical Birth Register (MBR) is kept by the National Board of Health and Welfare 
(NBHW). The register contains information on prenatal and perinatal variables related to 
nearly all pregnancies and births in Sweden since 1973, with approximately 2% complete 
missingness.128 The register was used to identify birth cohorts in Study I-III and to retrieve 
information on maternal pre-pregnancy body weight and height as well as other covariates in 
Study III. 
The Swedish Twin Register (STR) was established in the late 1950s and is maintained at 
the Department of Medical Epidemiology and Biostatistics, Karolinska Institutet. Data have 
been collected through multiple waves of questionnaires. The register currently contains over 
75,000 twin pairs with zygosity determined via questions about intra-pair similarity and 
validated by genotyping data.129 Data in this register were used to identify monozygotic and 
dizygotic twins in Study I. 
The Swedish National Patient Register (NPR) was established and is currently held by the 
NBHW.130 The register covers somatic inpatient care since 1964 and psychiatric inpatient 
care since 1973, with complete coverage achieved since 1987. Data on outpatient visits to 
specialist physicians in public care are available since 2001, even though the coverage is 
limited to approximately 80%. Information on primary care or other care services provided 
by non-physicians (e.g., psychologists and physiotherapists) is missing. For each patient, the 
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register contains discharge dates as well as primary and secondary diagnoses coded according 
to the ICD-8 (1969 –1986), ICD-9 (1987 – 1996) and ICD-10 (1997 – 2009). This register 
was used to identify ADHD cases (Study I-IV), suicide attempts (Study IV), and other 
psychiatric diagnoses as covariates (Study I, II and IV). 
The Prescribed Drug Register (PDR) covers information on all drugs prescribed and 
dispensed in ambulatory care to the entire population in Sweden since July 1, 2005.131 It 
contains data on active ingredients coded according to the anatomical therapeutic chemical 
(ATC) classification system, dispensed amount and dosage, prescribing and dispending dates, 
etc. The register was used to identify individuals who received prescriptions of ADHD 
medications in Study I–III and to define the time-varying treatment status by ADHD 
medications in Study IV. 
The Clinical Database for Child and Adolescent Psychiatry in Stockholm (Pastill) 
includes data on diagnoses according to the DSM-IV or the ICD-10 and dates of diagnoses 
from Child and Adolescent Mental Health Services in Stockholm County since 2001.132 The 
database was used to identify ADHD cases according to the DSM-IV and the ICD-10 
diagnostic criteria (Study I-III). 
The Military Service Conscription Register (MSCR) was introduced in 1901. It contains 
data on physical and psychological variables measured at age 18-20 for Swedish men who 
were conscripted for military service. In Sweden, military conscription was mandatory for all 
male citizens until 2007, with approximately 2–3% being exempted, mainly owing to severe 
handicaps or congenital disorders.133 In 2009, the obligatory military service was replaced by 
voluntary military service. The register was used to identify body weight and height of index 
persons in Study II. 
The Cause of Death Register (CDR) was established in 1952 and is updated annually. 
Complete coverage of the register has been achieved since 1961. The register contains 
mandatorily reported information on principle and contributing causes of deaths, coded 
according to the ICD system for all diseased individuals who were registered as living in 
Sweden at the time of death.134 The register was used to identify individuals who died by 
suicide (Study IV) and to define censoring points during the follow-ups (Study I, III, and IV). 
Longitudinal integration database for health insurance and labor market studies 
(LISA) was established in 1990 and is currently held by Statistics Sweden.135 The database is 
annually updated and contains information on, for example, highest level of education, 
unemployment, social benefits, and family income for all Swedish residents aged 16 years or 
older. Data on highest level of education (Study II and III) was retrieved from this register. 
 15 
1"
Dispensation of ADHD medication Off-treatment On-treatment 
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4.2 MAIN MEASURES 
4.2.1 ADHD 
ADHD cases were defined as individuals who received a diagnosis of HKD (ICD-9: 314; 
ICD-10: F90) according to the NPR, or a diagnosis of HKD and/or ADHD (DSM-IV: 314) 
according to Pastill, or a drug prescription of ADHD medication [i.e., methylphenidate 
(N06BA04), amphetamine (N06BA01), dexamphetamine (N06BA02), or atomoxetine 
(N06BA09)] according to the PDR during each study period. In Study I, information on 
ADHD diagnosis (a drug prescription was also based on a diagnosis) was used to define a 
time-varying exposure. In Study I and III, attained age at first-trackable ADHD diagnosis was 
used as a time-to-event outcome. In Study II, ADHD status was treated as a binary outcome 
(presence/absence). In Study IV, ADHD cases identified exclusively from the NPR 
constituted the study cohort. 
4.2.2 BMI 
In Study II, data on objectively measured body weight and height were retrieved from the 
MSCR.136 In Study III, information on self reported height and objectively measured weight 
at the first antenatal visit (around gestational week 10) were extracted from the MBR.137 In 
both studies, BMI was calculated as body weight in kilograms divided by height in meters 
squared, and subsequently categorized into underweight (BMI<18.5), normal weight 
(18.5≤BMI<25), overweight (25≤BMI<30), and obesity (BMI≥30) according to the criteria 
given by the WHO.73 Categorical BMI was used as an exposure in both Study II and III. 
4.2.3 Treatment status by ADHD medications 
Treatment status by ADHD medications was treated as a time-varying exposure in Study IV. 
Specifically, for each patient, we divided the entire follow-up from January 1st, 2006 to 
December 31st, 2009 into on- and off-treatment periods (Figure 4.1). An on-treatment period 
was defined as a time interval that covered a sequence of dispensations of ADHD 
medications, without any gap of more than 6 months (183 days) between two consecutive 
dispensations. The time periods not occupied by the on-treatment periods were defined as off-
treatment periods. The start of an on-treatment period was the date of the first dispensation 
and the end of the on-treatment period was the date of the last dispensation. We took 
dispensations in 2005 and 2010 into account when defining the treatment status over the first 
and the last periods during the follow-up (Figure 4.1). 
Figure 4.1: Treatment status by ADHD medications as a time-varying exposure 
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4.2.4 Suicide-related events 
In Study IV, suicide-related events were defined as attempted or completed suicides 
according to ICD-10 codes (X60-X84: intentional self-harm; Y10-Y34: event of 
undetermined intent) and identified from the NPR and the CDR, along with the dates of their 
occurrences. 
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5 METHODS 
5.1 GENETICALLY INFORMATIVE DESIGNS 
5.1.1 Familial aggregation and co-aggregation studies 
Familial aggregation studies are observational studies that assess the clustering of disease in 
family members due to shared genetic or environmental factors or both. Genetic origin is 
often assumed to be responsible for the clustering of disease if the change in the genetic 
relatedness between family members is mirrored by the change in the disease risk in the 
family members.138 
In a familial aggregation study, researchers estimate disease risk in study participants given 
family history of the same disease. One way to look at family history of a disease is that it 
serves as a proxy of the genetic susceptibility of a disease. Whether a participant is 
genetically susceptible to a disease is set at birth, but is considered unknown until at least one 
of his or her family members is diagnosed with the disease. The ascertainment of the genetic 
susceptibility can be carried out retrospectively via measuring the disease status of one or 
more close family members of the participant. For instance, when studying the familial 
aggregation of ADHD in first-degree relatives (i.e., parents, siblings, and offspring), 
researchers may be solely interested in the association between ADHD among index persons 
and ADHD among the relatives of the index persons, regardless of whether the index persons 
receive ADHD diagnosis before or after their relatives do. In this setting, it is logical to view 
the disease status, both for index person and relative, as a binary variable, and analyze the 
data in, for instance, logistic regression models. However, family members of a diseased 
individual may be more likely to seek medical care and receive diagnosis, possibly owing to 
increased awareness and concern about the disease. Accordingly, familial risks can be 
calculated using survival models to accommodate the time-varying effects of the disease 
status of index person on the risk of the same disease in his or her family members so as to 
provide estimates with better real-world implications in terms of disease risk prediction. 
Familial aggregation studies can be extended to familial co-aggregation of two diseases. In 
familial co-aggregation studies, the research interest lies in estimating the risk of one disease 
in study participants given family history of another. An example is a study of the association 
between ADHD among index persons and the suicide attempt among relatives of the index 
persons. Hudson JI et al. proposed a structural approach to study the familial co-aggregation 
of two diseases using DAGs.139 According to this approach, it is possible to test whether two 
diseases share etiological factors under certain assumptions. 
Figure 5.1 illustrates the rationale behind familial co-aggregation studies. In this DAG, FX is 
a latent factor representing familial causes unique for disease X. FX-Y is a latent factor 
denoting common familial causes for disease X and Y. Estimating familial co-aggregation of 
disease X and Y is to estimate the association between disease X in relative No.2 (X2) and 
disease Y in relative No.1 (Y1), which can be attributed to the open paths X2 ←!FX →!X1→!Y1 
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and X2 ←!FX-Y →!X1. It is noteworthy that the association exists only if at least one of FX and 
FX-Y is present. The hypothesis test for an etiological overlap between disease X and disease 
Y can be viewed as seeking evidence for the presence of FX-Y. A valid hypothesis test (i.e., a 
test of the presence of FX-Y that is not contaminated by the presence of FX) requires additional 
assumptions, such as an absence of a direct within-individual effect of disease Y on disease X 
and positive associations represented by all arrows.139 The plausibility of the assumptions 
largely depends on research question, researchers’ subject matter knowledge, and data 
quality. 
Figure 5.1: Directed acyclic graph for familial aggregation and co-aggregation studies. 
Figure modified from Hudson JI et al.139 
 
 
 
 
 
 
 
 
 
X1: Disease X in relative No.1; X2: Disease X in relative No.2; Y1: Disease Y in relative No.1; Y2: Disease Y in 
relative No.2; Y2: Disease Y in relative No.2; FX-Y: Common familial causes for Disease X and Y; FX: Familial 
causes unique for Disease X; FY: Familial causes unique for Disease Y; C1: Common causes for Disease X and 
Disease Y specific for relative No.1; C2: Common causes for Disease X and Disease Y specific for relative No.2; 
Relative No.1 and Relative No.2 can be first-, second-, or third-degree relatives. 
 
In register-based settings, disease status is often ascertained via registered clinical diagnosis 
and treated as a binary variable (presence or absence). However, the aforementioned 
approaches can also be applied to investigate familial aggregation or co-aggregation of 
certain behavioral traits or physiological conditions. 
5.1.2 Quasi-experimental studies 
Quasi-experimental studies are studies evaluating the impact of an exposure on an outcome 
without random assignment of study participants to exposed and unexposed groups. Despite 
the lack of randomization, this type of studies are designed to mimic randomized controlled 
trials with respect to protecting against confounding bias that can threaten the internal validity 
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of a study.140 Quasi-experimental designs based on family samples or measurements 
repeatedly taken from the same individual are genetically informative designs that can help 
control for unmeasured confounders such as genetic background. 
5.1.2.1 Sibling comparisons 
Sibling comparisons are widely used family-based quasi-experimental designs, especially in 
studies of associations between prenatal exposures and later health outcomes. In traditional 
epidemiologic research, unrelated individuals with different exposure levels are compared for 
prevalence or incidence of outcomes and confounding adjustment solely relies on researchers 
being able to identify confounders and reliably measure them. Sibling comparisons estimate 
exposure-outcome associations among differently exposed siblings within a nuclear family 
and, by design features, automatically account for familial confounding, i.e., confounding 
bias arising from all familial factors (both genetic and environmental factors) shared by 
siblings.116,141 In fact, these familial factors may not be objectively shared, but need to have 
identical effective influence on siblings.142 If the exposure under study is a parental trait, full 
sibling comparisons can preclude confounding due to passive gene-environment correlations 
(rGEs), because parents pass down their alleles randomly to their offspring during meiosis 
and the version of alleles carried by each offspring is thereby exposure-independent.55 When 
prenatal traits serve as exposures, confounding due to active and evocative rGEs can be ruled 
out as well because offspring cannot reversely select themselves into or elicit exposures 
preceding their own births.55 In addition, sibling comparisons can handle precisely measured 
covariates by multiple regression model adjustment in the same way as traditional 
epidemiologic research. Accordingly, significant within-family associations between prenatal 
exposure and later health outcome cannot be attributed to familial factors that make siblings 
similar and therefore may serve as more rigorous evidence for potential causal effects; non-
significant within-family associations, on the other hand, may indicate, among other things, 
that familial confounding is likely to play a role in population-level associations.141 In Study 
III, sibling-comparison was used to investigate the role of familial confounding in the 
association between high maternal pre-pregnancy BMI, a prenatal maternal trait, and 
offspring ADHD. 
5.1.2.2 Within-individual comparisons 
Within-individual comparisons represent a type of underused genetically informative designs, 
especially in pharmacoepidemiologic research. By using each study participant as his or her 
own control, within-individual comparisons automatically control for all time-constant 
factors (e.g., genetic background and baseline disease severity) within the same individual 
during the follow-up. Hence, when RCTs are not feasible for studying rare adverse events in 
relation to pharmacotherapies, observational studies using within-individual comparisons 
may serve as attractive alternatives. In addition, within-individual comparisons are appealing 
because of their potential to minimize bias derived from confounding by indication, i.e., 
indication for treatment is associated with the risk of outcome under study. In Study IV, we 
examined whether the use of ADHD medication was associated with an increased risk of 
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concomitant suicidal behavior. The study used within-individual comparisons to control for 
confounding due to the association between ADHD per se and suicidal behavior. This is 
reasonable because the association may to some extent be explained by (1) common genetic 
etiology between ADHD and suicidal behavior, (2) baseline severity of ADHD, and (3) other 
baseline comorbid psychiatric conditions; all these factors are relatively stable within the 
same individual. 
5.2 COHORT DESIGNS 
5.2.1 Standard cohort studies 
Cohort studies are a form of longitudinal studies. In a cohort study, an outcome-free study 
population is first identified. The participants are categorized according to their exposure 
status and subsequently followed over a certain length of time for the occurrence of an 
outcome event. If a cohort is a static cohort and all the participants have complete follow-up, 
we can compare the risk of the outcome between the exposed group and the unexposed 
group.143 If a cohort is a dynamic cohort in which not all participants have complete follow-
up and each participant contributes a certain length of time at risk, such data on the outcome 
(event) are called time-to-event data and should be analyzed in the framework of survival 
analysis. Study III and IV are cohort studies based on prospectively collected data in the 
Swedish national registers. 
5.2.2 Reconstructed cohort studies 
In this thesis, the familial aggregation and co-aggregation studies (Study I and II) can be 
viewed as reconstructed cohort studies, in which index persons defined the exposure (i.e., 
family history of a condition) and the relatives of the affected and unaffected index persons 
were “reconstructed” into exposed and unexposed groups. The relatives constituted the study 
cohort and defined the outcome.138 In Study I, ADHD status in index person was treated as a 
time-varying exposure and attained age at first ADHD diagnosis in the relative of the index 
person was used as a time-to-event outcome. The familial aggregation of ADHD was 
analyzed in the above-mentioned framework of survival analysis. In Study II, since it is 
unlikely that a male index person’s BMI would influence his relatives’ awareness or concern 
about ADHD, we treated ADHD in the relatives of the index persons as a binary outcome 
(presence/absence) and estimated the strength of the familial co-aggregation of ADHD and 
overweight/obesity using logistic regression models. 
5.3 STATISTICAL METHODS 
5.3.1 Cox proportional hazards models 
Cox proportional hazards models are widely applied statistical models for analyzing time-
to-event data. When using Cox models, researchers are interested in estimating hazard ratio 
(HR) as a function of all independent variables. The models assume that hazards for 
exposed group and unexposed group are proportional throughout follow-up, without 
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making additional assumption about the shape of baseline hazards.144 Large register-based 
data often have adequate power to detect even a slight violation of the proportionality. 
Under such circumstances, graphical assessment of the violations of the proportional 
hazards assumption should be carried out. If the assumption is found to be severely 
violated, stratified analyses should be performed accordingly. In Cox models, HRs are 
automatically adjusted for the underlying time scale such as attained age. 
5.3.2 Logistic regression models 
Logistic regression models are commonly employed in epidemiological research when 
outcome variable is binary. The models assume that the log-odds of a binary outcome 
variable has a linear relationship with a set of covariates including exposure. The logistic 
regression coefficient of the exposure variable is interpreted as the change in the log-odds of 
the outcome for every unit change in the exposure while holding all other covariates constant. 
By taking the exponential of the regression coefficient, an OR (i.e., the odds of being exposed 
given the presence of the outcome compared with the odds of being exposed given the 
absence of the outcome) can be obtained. 
5.3.3 Clustered data 
Studies using large register-based data increase the potential of data clustering. Examples of 
clustered data are measurements taken from the same family or repeatedly taken from the 
same individual. Most statistical models assume independence between observations, but data 
within a cluster tend to be positively correlated. Failure to address the non-independence of 
clustered data would lead to underestimation of standard errors and p-values. Thus, special 
attention should be given to analyses of clustered data to avoid misinterpretations due to 
incorrect precisions. In between-cluster analyses, a sandwich formula145 can be used to 
correct standard errors. The formula accounts for model misspecifications due to data 
clustering and generates so-called robust standard errors. In this thesis, robust standard errors 
were estimated in between-cluster analyses in all four studies. 
In within-cluster analyses (e.g. sibling-comparison analyses and within-individual analyses), 
clustered data are not threats to the validity of a study; rather, they can be utilized to control 
for unmeasured cluster-constant confounding. In this thesis, we used stratified Cox 
proportional hazards models, which incorporate fixed effects models into Cox proportional 
hazards models, to investigate exposure-outcome associations in Study III and IV. A 
stratified Cox model can be viewed as an ordinary Cox model conditioning on each cluster. 
While ordinary Cox models estimate exposure-outcome associations between unrelated 
individuals, stratified Cox models estimate exposure-outcome associations within each 
cluster, assuming with-cluster association is constant across all clusters.  
  
 22 
5.4 METHODS BY STUDY 
5.4.1 Overview 
 
Study Participants Measures Statistical analyses 
I Relative pairs of varying 
degrees of genetic relatedness 
(n = 8,263,689) identified 
from individuals born in 
Sweden between1985 and 
2006 (n = 1,656,943) 
Time-varying exposure: ADHD 
status in index persons 
Outcome: Time to first ADHD 
diagnosis in relatives of index 
persons 
Covariates: Relative’s birth year 
Cox proportional 
hazards models and 
robust sandwich 
estimator 
II Male index persons born 
between1973 and 1992 (n = 
472,735) and their male and 
female siblings (n = 523,237) 
and cousins (n = 2,138,440) 
Exposure: BMI in index persons 
Outcome: ADHD in index 
persons, ADHD in relatives 
Covariates: Index person’s birth 
year and ADHD status 
Logistic regression 
models and robust 
sandwich estimator 
III Individuals born in Sweden 
between 1992 and 2000 (n = 
673,632) 
Exposure: Maternal pre-
pregnancy BMI 
Outcome: Time to first ADHD 
diagnosis in offspring 
Covariates: Offspring sex, birth 
order, birth year, mother’s country 
of birth, highest education, age at 
delivery, smoking during 
pregnancy, and cohabitation with 
child’s father at childbirth  
Entire cohort: Cox 
proportional hazards 
model with robust 
sandwich estimator 
Sibling comparison: 
Stratified Cox 
proportional hazard 
model 
IV Patients with ADHD born 
between 1960 and 1996 (n = 
37,936) 
Time-varying exposure: 
Treatment status by ADHD 
medications 
Outcome: Time to first suicide-
related event 
Covariates: Sex, age, previous 
number of treatment switches, and 
previous number of suicide 
attempts 
Entire cohort: Cox 
proportional hazards 
model with robust 
sandwich estimator 
Within-individual: 
Stratified Cox 
proportional hazards 
model 
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5.4.2 Study I–IV 
Study I 
By linking the MBR, the MGR, and the STR, we identified all possible relative pairs of 
monozygotic twins, full siblings, maternal and paternal half siblings, full cousins and half 
cousins from individuals born alive in Sweden between 1985 and 2006. Full cousins were 
defined as children of full siblings. Half cousins were defined as children of half siblings. 
Children of monozygotic twins and individuals who shared both sets of grandparents (i.e., 
double first cousins) were excluded from the cousin sample because they were genetically 
equivalent to half siblings. Individuals from single-child nuclear families were also excluded 
from the cousin sample to ensure that the cousin sample and the sibling sample were 
comparable. All individuals were followed from their third birthday until first ADHD 
diagnosis, death, emigration, or December 31, 2009, whichever occurred first. 
For descriptive purposes, we plotted cumulative probability of ADHD diagnosis up to 20 
years of age in all participants, all siblings, and all cousins, using the Kaplan-Meier method.  
We then calculated crude and birth year adjusted HRs for ADHD diagnosis in relatives of 
index persons using Cox proportional hazards models, with ADHD diagnosis in index person 
as a time-varying exposure and attained age of relative as the underlying time scale. Since 
each family typically contributed more than one pair of relatives, we estimated robust 
standard errors to account for the non-independence of the family-clustered data.  
To assess the potential importance of shared environmental influences, we tested whether 
HRs significantly differ between maternal half siblings and paternal half siblings. Maternal 
half sibling pairs and paternal half-sibling pairs both share 25% of their segregating genes on 
average, but maternal half-siblings might share more environmental factors compared with 
paternal half-siblings for two reasons. First, children born to the same mother tend to share 
more factors related to intrauterine environment.146 Second children in Sweden continued to 
live predominantly with their mothers following parental separation during the study 
period.147 Consequently, if shared environmental experiences were responsible for some of 
the association, we would expect higher HR in maternal half siblings than in paternal half 
siblings. 
Furthermore, we carried out several subgroup analyses in full siblings. To examine sex-
specific influence on the familial aggregation, we performed analyses stratified on sex 
combination of index persons and their siblings. When assessing the impact of persistence of 
ADHD into adulthood, we restricted analyses to sibling pairs born during 1985 – 1991, and 
further categorized ADHD affected index persons by their age at last diagnosis (<18 / 
≥18years). 
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Study II 
By linking the MBR, the MSCR, and the MGR, we identified male index persons born alive 
in Sweden between 1973 and 1992 with information on BMI and their male and female 
siblings and cousins born in Sweden between 1973 and 2002. Index persons older than 21 
years of age at conscription were excluded to diminish age-related variation in BMI, as the 
vast majority of the index persons were conscripted at age 18-20. Index persons with BMI 
less than 18.5 were also excluded, because the assumptions used in the study might not apply 
to the relationship between underweight and ADHD. 
Logistic regression models were used to estimate ORs and 95% CIs to assess (1) the 
association between ADHD and overweight/obesity in index persons and (2) the familial co-
aggregation of ADHD and overweight/obesity, i.e., the association between ADHD in 
relatives of index persons and overweight/obesity in index persons. Robust standard errors 
were calculated to account for the non-independence of the clustered data. 
We used a DAG (Figure 5.4.2.1) to explain the underlying mechanisms of the potential co-
aggregation of ADHD and overweight/obesity within families. 
Figure 5.4.2.1: Familial co-aggregation of ADHD and overweight/obesity 
 
 
 
 
 
 
 
 
 
YA1: ADHD in index person; YB1: Overweight/obesity in index person; YA2: ADHD in index person’s relative; 
YB2: Overweight/obesity in index person’s relative; F: Common familial causes for ADHD and 
overweight/obesity; CA: Familial causes for ADHD alone; CB: Familial causes for overweight/obesity alone; C1: 
Common causes for ADHD and overweight/obesity specific for index person; C2: Common causes for ADHD 
and overweight/obesity specific for index person’s relative. 
 
An important assumption in the DAG is that there is no direct within-individual effect of 
overweight/obesity on ADHD, i.e., ADHD cannot be caused by overweight/obesity. This 
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assumption is plausible because ADHD status in the present study was ascertained via 
clinical diagnosis rather than cross-sectional questionnaires where ADHD-like symptoms 
may derive from overweight/obesity related conditions such as sleeping disorders.82 
However, the DAG allows for a direct within-individual effect of ADHD on 
overweight/obesity, i.e., ADHD may cause overweight/obesity. 
We used two models to estimate the associations between ADHD in relatives of index 
persons and overweight/obesity in index persons. Model 1 was used to demonstrate the 
familial clustering of the two conditions due to any factors shared by family members (CA 
and F in this study). This model was not adjusted for ADHD status of index person (YA1). 
Therefore, ORs measured the association that can be attributed to the pathway of interest (YB1 ←!F!→!YA2) and an additional pathway mediated by the direct effect of ADHD on obesity 
(YB1 ←!YA1 ←!CA →!YA2). 
Model 2 was used to detect the presence of common familial causes for ADHD and 
overweight/obesity (F). This model was adjusted for ADHD status of index person (YA1). 
Such adjustment blocked the path YB1 ←!YA1 ←!CA →!YA2 but opened two previously 
blocked paths, YB1 ←!C1 →!YA1 ← CA →!YA2 and YB1 ←!F!→!YA1 ←!CA!→YA2.148 Under 
realistic scenarios the first path (YB1 ←!C1 →!YA1 ← CA →!YA2) is likely to induce an inverse 
association–component between YB1 and YA2, because of the adjustment of the collider YA1 
and assumption of positive associations represented by all arrows. Thus, if the net association 
is positive (e.g. ORs > 1), we may conclude that the path YB1 ←!F!→!YA2 and/or the path YB1 ←!F!→!YA1 ←!CA!→YA2 is present. As both paths go through F, we may thus conclude that F 
is present. Note that F may also cause the occurrence of ADHD and overweight/obesity to the 
same individual. The presence of F indicates an etiological overlap between ADHD and 
overweight/obesity. 
 
Study III 
We identified eligible individuals born in Sweden between 1992 and 2000 from the MBR. 
We linked the cohort to the MGR to further identify full biological siblings nested in the 
cohort. All individuals were followed from their third birthday until first ADHD diagnosis, 
death, emigration, or December 31, 2009, whichever occurred first. 
Cox proportional hazards models were used to estimate population-average HRs for time to 
first-ever ADHD diagnosis and robust standard errors were used to adjust the 95% CIs for the 
presence of familial clustering. Individuals born to mothers of underweight, overweight, and 
obesity were compared with individuals born to mothers of normal weight. The models were 
adjusted for offspring sex, birth order, birth year, mother’s country of birth, highest 
education, age at delivery, smoking during pregnancy, and cohabitation with child’s father at 
childbirth. 
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Stratified Cox proportional hazards models were used for sibling comparisons, with each set 
of full siblings as a separate stratum. The models were adjusted for the aforementioned 
covariates, except for mother’s country of birth and highest education, because these two 
covariates were constant within families and thus already adjusted by the sibling-comparison 
design. We also examined the studied association when (1) pooling together the subgroups 
exposed to maternal pre-pregnancy overweight and obesity and (2) using continuous BMI as 
the exposure. 
We performed additional analyses stratified on the pattern of between-pregnancy variation in 
BMI (normal weight – normal weight, normal weight – overweight/obesity, 
overweight/obesity – normal weight, and overweight/obesity – overweight/obesity) in a 
subsample consisting of first- and second-born siblings from each family. Continuous BMI 
was used for these analyses to boost statistical power. 
 
Study IV 
We identified individuals born between 1960 and 1996 with at least one ADHD diagnosis 
from the NPR. We linked the cohort to the PDR to retrieve information on dispensed ADHD 
medications and dispensing dates for all participants. 
Figure 5.4.2.2: Data preparation for an ADHD patient with repeated suicide attempts during 
the follow-up 
 
 
 
 
 
 
Treatment status by ADHD medications was treated as a time-varying exposure. We divided 
the follow-up time into consecutive periods for each participant (Figure 5.4.2.2). A new 
period started after a treatment switch (i.e., from on-treatment to off-treatment or vice versa) 
or a suicide attempt. A period following a treatment switch was left truncated at the time of 
the switch; a period following a suicide attempt started at baseline (i.e., a patient continued 
contributing time of follow-up after a suicide attempt). A period ending with a treatment 
switch, emigration, or death due to other causes than suicide was considered censored. All 
participants were followed from January 1, 2006 to December 31, 2009 for any suicide-
related events, death, or emigration. 
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We performed both between-individual analyses and within-individual analyses to examine 
the association between the use of ADHD medication and concomitant suicidal behavior. 
Cox proportional hazards models were used for between-individual analyses, with robust 
standard errors accounting for correlated data from the same individual. These models were 
adjusted for sex and categorical age per year. Stratified Cox proportional hazards models 
were used for within-individual analyses, with each individual as a separate stratum. These 
models were adjusted for categorical age in years, previous number of treatment switches, 
and previous number of suicide attempts. 
Several sensitivity analyses were conducted to test the robustness of the results. Specifically, 
two alternative exposure definitions were used to examine the potential influence of exposure 
time misclassification. First, we set the end of each treatment period to be 30 days after the 
last drug dispensation. Second, we defined treatment status by using a three-month cut-off 
(i.e., on-treatment period was defined as a sequence of drug dispensations without 
discontinuation of more than 92 days). Furthermore, we repeated between-individual and 
within-individual analyses in subgroups: stimulant users, non-stimulant/mixed users, a 
younger cohort born during 1982 – 1996 (baseline age 10 – 24 years), and an older cohort 
born during 1960 – 1981 (baseline age 25 – 46 years). 
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6 ETHICAL CONSIDERATIONS 
Ethical considerations in research are mainly dealing with finding a sensible balance between 
the intended public good and the level of personal invasion. According to current Swedish 
regulation, informed consent is not required when register data are used for the purpose of 
research. However, register-based research should be performed in the corresponding data 
protection framework to ensure personal integrity of research participants. In this thesis, data 
on demographic characteristics and healthcare were routinely collected by the Swedish 
NBHW and stored in the national registers. Such register data were anonymized before being 
used for research. Specifically, Statistics Sweden, an independent government agency, was 
responsible for substituting PINs with random identifiers. The code used for linking the PINs 
and the random identifiers was deleted immediately afterwards to ensure no integrity-
sensitive information could be traced back to individual participants. In this thesis, all studies 
have been approved by the ethics committee at Karolinska Institutet, Stockholm. 
Good research includes accurately and effectively communicating research findings to the 
public. General readers do not gain scientific knowledge through peer-reviewed journals or 
textbooks as researchers do. It is preferable that researchers provide non-technical 
interpretations of research findings along with clear descriptions of study participants and the 
generalizability of the findings through mass media such as television, radio, newspapers, and 
the Internet. Some findings in this thesis emphasized the importance of genetic origin in the 
development of ADHD and its associated adverse health outcomes. These findings might be 
mistakenly interpreted as showing that individuals from families at risk are deemed to suffer 
from mental health issues. Such simplistic interpretation fails to see that the word 
“predisposition” per se denotes a tendency rather than a destiny and implies the role of a 
complex interplay between multiple genetic and non-genetic factors (e.g. environmental 
factors and life experiences) in the development of a complex disorder. Although the role of 
environmental factors have not been the core focus of this thesis, the results presented herein 
do not imply that environmental factors are not of importance. 
Despite the valuable implication in scientific literature, negative research findings are often 
under-reported, which constitutes a major publication bias. In this thesis, we have reported 
null findings in Study III and IV. We believe the null findings may be beneficial to the 
planning of future research and implicated in health promotion and disease prevention. 
However, statistically non-significant results suggest a lack of evidence for rejecting the null 
hypothesis and should not be viewed as evidence for no associations or no increased risks. 
This has been carefully discussed in Study III and IV via explicitly pointing out that an 
increased risk should not be fully ruled out given the upper limit of the confidence interval. 
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7 RESULTS 
7.1 FAMILIAL AGGREGATION OF ADHD (STUDY I) 
In this study, we quantified the familial aggregation of ADHD in a Swedish family sample 
consisting of 8,618 monozygotic twin pairs, 26,458 dizygotic twin pairs, 2,030,117 full 
sibling pairs, 315,267 maternal half sibling pairs, 312,593 paternal half sibling pairs, 
4,612,179 full cousin pairs, and 958,457 half cousin pairs constructed from 1,656,943 unique 
individuals born between 1985 and 2006. During the follow-up, 31,865 individuals received 
ADHD diagnosis (male to female ratio 3.7). 
Cumulative probability of ADHD diagnosis 
The cumulative probability of ADHD diagnosis at age 20 for all participants was 3.7% 
(Figure 7.1 a), which was comparable to the cumulative probabilities for siblings and cousins 
of unaffected index persons (both around 3.6%). The cumulative probability of ADHD 
diagnosis at age 20 was 25.3% for siblings (Figure 7.1 b) and 10.0% for cousins (Figure 7.1 
c) of ADHD affected index persons. 
 
Figure 7.1: Cumulative probability of ADHD diagnosis in all participants, all siblings, and 
all cousins 
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Familial aggregation of ADHD measured by HRs 
ADHD aggregated in families, with full siblings of ADHD affected index persons having a 
more than 8-fold increase in the rate of ADHD diagnosis compared with full siblings of 
unaffected index persons. The strength of the familial aggregation decreased with decreasing 
genetic relatedness between family members (Figure 7.2). Maternal half siblings had 
significantly higher HR compared with paternal half siblings (p = 0.0035). 
 
Figure 7.2: Familial aggregation of ADHD among relatives of varying degrees of genetic 
relatedness 
 
 
 
 
 
 
In full siblings, males had generally higher rate of ADHD than females. HRs did not 
significantly differ by index person’s sex either in male siblings (p = 0.0636) or in female 
siblings (p = 0.3400) (Table 7.1). Siblings of index persons with ADHD diagnosis persisting 
into adulthood had increased rate of ADHD compared with siblings of index persons with 
ADHD diagnosis but only prior to adulthood (Table 7.1). 
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Figure 7.2 Familial aggregation of ADHD among relative pairs of varying degrees of genetic relatedness  
 
Monozygotic twins 
 
70.45 (38.19–129.96) 
Dizygotic twins 8.44 (5.87–12.14) 
Full siblings 8.27 (7.86–8.70) 
Maternal half siblings 2.86 (2.61–3.13) 
Paternal half siblings 2.31 (2.07–2.58) 
Full Cousins 2.24 (2.11–2.38) 
Half cousins 1.47 (1.35–1.61) 
Relation to index person  Birth year adjusted HR (95% CI) 0.5 1.0 2.0 4.0 8.0 16.0 32.0 64.0 128.0
Birth year adjusted HR (95%CI)
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Table 7.1: Aggregation of ADHD in full sibling pairs by index person’s sex and persistence 
of ADHD into adulthood 
  
Rate of ADHD per 100 000 person-years 
  Full siblings 
 
Exposed Unexposed 
 
HR (95% CI) 
Sex combinationa 
     Sibling Index person 
Male Male  2468 207  7.61 (7.07 – 8.19) 
Male Female  2974 219  8.57 (7.61 – 9.65) 
Female Male 
 
1373 75 
 
10.05 (9.15 – 11.03) 
Female Female 
 
1709 81 
 
10.85 (9.30 – 12.66) 
Index person’s age at last ADHD diagnosisb 
< 18 years  668 87  4.68 (3.83 – 5.72) 
≥ 18 years  1724 87  11.49 (9.97 – 13.25) 
aAdjusted for birth year 
bPresence of diagnosis at age 18 or older was used as a proxy for persistence of ADHD into adulthood; the analyses were 
performed in full siblings born during 1985 – 1991 
 
7.2 FAMILIAL CO-AGGREGATION OF ADHD AND HIGH BMI (STUDY II) 
Study II aimed to quantify the familial co-aggregation of ADHD and overweight/obesity in 
male index persons and their siblings and cousins, followed by testing the hypothesis that 
ADHD and overweight/obesity share etiological factors. A total of 523,237 siblings and 
2,138,440 cousins for 473,735 male index persons were identified. Among index persons, 
384 525 (81.3%) had normal body weight, 68,906 (14.6%) were overweight, and 19,304 
(4.1%) had obesity. 
Table 7.2: Familial co-aggregation of ADHD and overweight/obesity 
 OR (95% CI) 
 Overweight Obesity 
Siblings !! !!
!
Model 1 1.14 (1.05 – 1.24) 1.43 (1.24 – 1.62) 
!
Model 2 1.13 (1.04 – 1.22) 1.38 (1.21 – 1.57) 
Cousins   
 
!
Model 1 1.11 (1.07 – 1.15) 1.30 (1.22 – 1.37) 
  Model 2 1.11 (1.07 – 1.15) 1.29 (1.22 – 1.36) 
Model 1: adjusted for birth year of index persons 
Model 2: adjusted for birth year and ADHD status of index person 
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Analyses in index persons 
Among male index persons, ADHD was positively associated with overweight (OR = 1.31, 
CI = 1.19 – 1.44) and obesity (OR = 2.00, CI = 1.74 – 2.30). The results were adjusted for 
birth year. 
Analyses in siblings and cousins 
Before adjusting for ADHD status of index person (Sibling Model 1 in Table 7.2), ADHD in 
siblings of index persons was significantly associated with overweight/obesity in index 
persons. After adjusting for ADHD status of index person (Sibling Model 2 in Table 7.2), the 
associations remained significant. Similar results were also observed among index persons 
and their cousins. 
7.3 MATERNAL PRE-PREGNANCY BMI AND OFFSPRING ADHD (STUDY III) 
In Study III, we examined whether the association between maternal pre-pregnancy BMI and 
offspring ADHD was consistent with a causal hypothesis or better explained by familial 
confounding. The study cohort was composed of 673,632 eligible individuals, including 
272,790 full biological siblings nested within 130,060 families. 
Crude models showed that maternal pre-pregnancy underweight, overweight, and obesity 
were all associated with increased risk of offspring ADHD in the entire cohort. After 
adjusting for measured covariates, the associations for overweight and obesity were slightly 
attenuated but remained, whereas the association for underweight completely disappeared. 
Sibling comparisons demonstrated that the observed associations in the entire cohort were 
largely attenuated to null after adjusting for familial factors shared by siblings (Figure 7.3). 
Figure 7.3: Associations between maternal pre-pregnancy BMI and offspring ADHD 
 
 
 
 
 
 
 
 
 
Adjusted model: Adjusted for offspring sex, birth order, year of birth, mother’s country of birth, highest maternal education, 
maternal age at delivery, smoking during pregnancy, and cohabitation with child’s father at childbirth. 
Sibling model: Adjusted for offspring sex, birth order, year of birth, maternal age at delivery, smoking during pregnancy, and 
cohabitation with child’s father at childbirth. 
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The null effect persisted in the sibling comparison when subgroups of overweight and obesity 
were pooled together (HR = 0.98; 95% CI = 0.83 – 1.17) and when continuous BMI was used 
as exposure (HRcontinuous BMI = 0.99; 95%CI = 0.96 – 1.02). 
Among first- and second-born siblings, analyses stratified on pattern of maternal variation in 
BMI between pregnancies revealed that no significant increase in continuous BMI associated 
with offspring ADHD (Table 7.3). 
Table 7.3: Associations between maternal pre-pregnancy BMI and offspring ADHD by 
pattern of variation in BMI between pregnancies 
Variation in BMI  HR (95%CI) 
First pregnancy Second pregnancy  Entire cohorta  Sibling comparisona 
Normal weight Normal weight  1.02 (1.00 – 1.05)  1.05 (0.97 – 1.13) 
Normal weight Overweight/Obesity  1.05 (1.01 – 1.08)  1.00 (0.93 – 1.08) 
Overweight/Obesity Normal weight  1.01 (0.95 – 1.07)  0.85 (0.67 – 1.08) 
Overweight/Obesity Overweight/Obesity  1.06 (1.04 – 1.07)  0.97 (0.93 – 1.02) 
aAdjusted for offspring sex and birth order; BMI was analyzed as a continuous variable 
7.4 ADHD MEDICATION AND SUICIDAL BEHAVIOR (STUDY IV) 
Study IV aimed to investigate whether the use of ADHD medication was associated with an 
increased risk of concomitant suicidal behaviour using within-individual comparisons to 
control for time-constant factors within the same individual. A total of 7,019 suicide-related 
events occurred to 37,936 patients with ADHD during 150,721 person years of follow-up.  
Figure 7.4: Association between the use of ADHD medication and concomitant suicidal 
behavior during 2006-2009 
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Between-individual analyses showed that the rate of suicide-related events was 30% higher 
during on-treatment periods compared to off-treatment periods. HRs among males and 
females were similar in magnitude (Figure 7.4). 
In contrast, within-individual analyses demonstrated no evidence for an increased rate of 
suicide-related events associated with the use of ADHD medication; in fact, the results 
indicated a 10% reduction in the rate of suicide-related events during on-treatment periods 
relative to the rate during off-treatment periods (Figure 7.4). 
When alternative definitions of on- and off-treatment periods were used, both between- and 
within-individual comparisons yielded similar results to the main analyses (Table 7.4). In 
other sensitivity analyses, between-individual comparisons showed that the use of ADHD 
medication was associated with an increased rate of suicide-related events in all subgroups 
except stimulant users. When on- and off-treatment periods were compared within the same 
individual, no increased rate was observed in any subgroup and a 19% decrease in the rate of 
suicide-related events appeared to be associated with the use of medication among stimulant 
users (Table 7.4). 
Table 7.4: Sensitivity analyses for the association between the use of ADHD medication and 
the rate of suicide-related events in subgroups 
 HR (95% CI) 
Sensitivity analyses Between-individuala Within-individualb 
Exposure definition   
On-treatment period ended 30 days after last prescription 1.39 (1.27 – 1.53) 0.96 (0.86 – 1.08) 
Treatment status defined by 3 month cut-off 1.40 (1.26 – 1.56) 0.90 (0.80 – 1.01) 
Subgroup   
Stimulant users 1.02 (0.90  – 1.16) 0.81 (0.70 – 0.94) 
Non-stimulant/mixed users 1.49 (1.27 – 1.76) 0.96 (0.77 – 1.20) 
        Stimulant on-treatment vs. off-treatment 1.45 (1.22 – 1.73) 0.93 (0.72 – 1.20) 
        Non-stimulant on-treatment vs. off-treatment  1.48 (1.17 – 1.88) 0.96 (0.72 – 1.30) 
Younger cohort born during 1982 – 1996 1.17 (1.05 – 1.31) 0.92 (0.79 – 1.07) 
Older cohort born during 1960 – 1981 1.39 (1.20 – 1.61) 0.82 (0.68 – 0.99) 
aAdjusted for sex and categorical age 
bAdjusted for categorical age, previous number of treatment switches, and previous number of suicide attempts 
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8 DISCUSSION 
8.1 MAIN FINDINGS AND INTERPRETATIONS 
8.1.1 ADHD aggregates in families 
In Study I, we demonstrated the familial aggregation of ADHD in to date the largest Swedish 
family sample. The observed familial aggregation of ADHD increased with increasing 
genetic relatedness between family members. Full siblings of index persons with ADHD had 
a more than eight-fold increased rate of ADHD compared with full siblings of index persons 
without ADHD. The findings are consistent with previously reported relative recurrence risk 
of ADHD in siblings.149 
In line with previous quantitative and molecular genetic studies,150,151 genetic origins may 
explain the pattern of familial aggregation of ADHD among close and distant relatives. In 
contrast to previous twin research,152 our finding that maternal half siblings had more 
pronounced HR compared with paternal half siblings suggests that part of the familial 
aggregation of ADHD is due to shared environmental influence. Half siblings share on 
average 25% of their segregating genes, but compared with paternal half siblings, maternal 
half siblings tend to share more environmental factors related to pregnancy, including 
intrauterine environment and perinatal conditions.146 In addition, paternal discrepancy may 
account for the slightly diminished HR in paternal half siblings. Paternal discrepancy occurs 
when the identified biological father of a child is in fact not the true biological father. One 
review based on 17 studies, including a Swedish study performed in1980, has reported a 
median proportion of paternal discrepancy of 3.7%.153 In the presence of paternal 
discrepancy, the assumed paternal half siblings are genetically equivalent to unrelated 
individuals. Furthermore, we observed higher than average baseline rate of ADHD diagnosis 
among half siblings, which suggests that having a half sibling might serve as an indicator of 
encountering more negative life events,154 or that interpersonal traits correlated with the 
genetic liability to ADHD are over-represented among the parents of half siblings. 
As expected,155 more males than females received ADHD diagnosis, giving a male to female 
ratio of 3.7. Despite the difference in the baseline rate of ADHD between males and females, 
HR did not significantly differ by the sex of the index persons; thus, it is reasonable to 
assume similar etiology of ADHD for males and females. Consistent with prior studies,156,157 
we observed that full siblings of index persons with ADHD diagnosis at age 18 or older were 
at higher risk of ADHD than full sibling of index persons with ADHD diagnosis but only 
before age 18. The results indicate that persistence of ADHD into adulthood is associated 
with a stronger genetic load compared to remission of ADHD prior to adulthood,40,158 which 
makes family members of individuals with persistent ADHD an important target group for 
diagnostic screening. 
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8.1.2 ADHD and overweight/obesity share etiological factors  
In Study II, we found that ADHD and overweight/obesity were associated within male index 
persons and co-aggregated within families. Males with ADHD were found to have two-fold 
increased odds of obesity compared to males without ADHD. The OR was higher than 
previously estimated according to a recent meta-analysis.79 The familial co-aggregation of 
ADHD and overweight/obesity can be jointly explained by (1) the familial aggregation of 
ADHD, along with the direct within-individual effect of ADHD on overweight/obesity, and 
(2) common familial causes for ADHD and overweight/obesity. After adjusting for the 
ADHD status of the index person, the positive associations between overweight/obesity in 
index persons and ADHD in relatives of index persons remained significant, suggesting that 
familial causes for ADHD and overweight/obesity may lead to the familial co-aggregation of 
the two conditions even in the absence of a direct within-individual effect of ADHD on 
overweight/obesity. The association between ADHD and overweight/obesity within index 
persons can thereby be, at least in part, attributed to an etiological overlap between ADHD 
and overweight/obesity. 
In Study III, analyses in the entire cohort showed that maternal pre-pregnancy overweight 
and obesity were both associated with increased risk of offspring ADHD even after adjusting 
for several measured covariates such as birth order and maternal age at delivery. The 
magnitude of the observed population-level associations was similar to previously 
estimated.159,160 However, the associations lacked statistical significance in sibling 
comparisons when all factors shared by siblings were accounted for by the study design. 
Taken together, the causality of the associations under study is not evident; the findings 
indicate substantial influence of familial confounding on the population-level associations 
between high maternal pre-pregnancy BMI and offspring ADHD. Familial confounding in 
this study, by definition, arises from common familial causes for high maternal pre-
pregnancy BMI and offspring ADHD. Another way of looking at the familial confounding is 
that it causes the familial co-aggregation of high BMI and ADHD in mothers and their 
offspring. Hence, the findings from Study II and III essentially point to the same conclusion 
that ADHD and overweight/obesity share etiological factors. The study also highlighted that 
confounding adjustment solely relying on measured covariates is unlikely to be sufficient in 
epidemiologic research. This reiterates that genetically informative designs such as sibling 
comparisons, if used wisely, may provide more rigorous tests of competing hypotheses and 
help make less biased causal inferences in observational studies.141 
Previous research on ADHD and overweight/obesity has predominantly focused on 
estimating the association between the two conditions,79 with the underlying mechanisms of 
the association being largely unknown. Despite the possibility of ADHD causing obesity 
through abnormal eating behavior in response to deficient inhibitory control, poor planning, 
and restlessness,80 findings from Study II and III suggested that an etiological overlap 
between ADHD and overweight/obesity may also account for the co-occurrence of the two 
conditions to the same individual. Study II and Study III to some extent complement each 
other with regards to sex differences: BMI in male index persons were used in Study II, while 
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BMI in female index persons were used in Study III. Thus, the familial co-aggregation of 
BMI and ADHD in both males and females has been investigated. Previous literature has 
linked the common neurobiological dysfunctions of ADHD and obesity to reward deficiency 
due to changes in mesolimbic and mesocortical dopamine pathways.161,162 Such reward 
deficiency might act as a common distal causal component leading to the development of 
ADHD and obesity via different biological mechanisms. In addition, mutations in the 
melanocortin 4 receptor gene and brain-derived neurotrophic factor gene variants have 
showed possible associations with both ADHD and obesity, even though the evidence is 
inconsistent.85,163,164 A recent meta-analysis based on more than 300,000 individuals 
identified 97 genome-wide significant loci accounting for up to 2.7% of BMI variation.84 
Similar level of progress in molecular genetic research on ADHD has not yet been 
achieved.43 More research is needed to determine the degree to which the association between 
ADHD and overweight/obesity might be driven by their etiological overlap. Apart from 
family-wide environmental risk, future genetic studies seeking for common pleiotropic 
genetic variants regulating both ADHD and BMI are warranted and may lead towards further 
exploration of novel effective treatments for both ADHD and overweight/obesity. 
8.1.3 No evidence for an increased risk of concomitant suicidal behavior 
associated with the use of ADHD medication 
In study IV, when comparing different individuals over on-treatment periods and off-
treatment periods (between-individual analyses), we observed a 30% increase in the rate of 
suicide-related events associated with the use of ADHD medication. The association 
disappeared in within-individual analyses in which each individual was compared with him 
or herself. If anything, the results pointed to a potential protective effect of ADHD 
medication on suicidal behavior, particularly for males and stimulant users. 
To the best of our knowledge, this is the first nationwide longitudinal study investigating 
ADHD medication in relation to suicidal behavior. In within-individual analyses, we 
accounted for both measured time-varying confounding factors, including age, previous 
number of suicide attempts, and previous number of treatment switches, and unmeasured 
time-constant factors such as baseline severity of ADHD and its comorbid psychiatric 
conditions as well as genetic susceptibility to both ADHD and suicidal behavior. The non-
significant findings from the within-individual comparisons suggest that the increased rate of 
suicide-related events associated with the use of medication in between-individual analyses 
might be due to unmeasured time-constant confounding factors. 
In between-individual analyses, off-treatment periods were contributed by medication-free 
patients and patients with treatment switches, while on-treatment periods were contributed by 
patients with treatment switches and individuals on medication throughout the follow-up. 
Compared to patients with mild ADHD, patients suffering from more severe forms of ADHD 
and other comorbidities such as mood disorder and substance abuse disorder are more likely 
to be treated by medication and more inclined to commit suicide or suicide attempt. In other 
words, the significant associations observed in between-individual analyses were possibly 
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confounded by increased severity of ADHD and high rate of comorbid conditions, a 
phenomenon commonly referred to as confounding by indication. The within-individual 
comparisons to a large extent ruled out bias due to confounding by indication, because the 
severity of ADHD and its comorbid conditions within the same individual was assumed to be 
relatively stable over time. 
There are several possible explanations for the decreased rate of suicide-related events 
associated with the use of medication among male patients and stimulant users in within-
individual analyses. First, this inverse association may represent a protective effect of ADHD 
medication on suicidal behavior. Such protective effect is biologically plausible in 
consideration of the well-documented efficacy of ADHD medication in symptom reduction, 
including reduction in both attentive and impulsive symptoms. Impulsive behavior is 
overrepresented by males and impulsivity has once been suggested as a promising 
intermediate phenotype for molecular genetic research in suicidal behavior.91 Thus a 
protective effect of ADHD medication on suicidal behavior might be mediated by the 
improvement of impulsive symptoms. Nevertheless, the protective effect was observed only 
among stimulant users but not non-stimulant/mixed users, possibly owing to the fact that 
stimulant users suffered from less complex ADHD and other psychiatric symptoms compared 
to non-stimulant/mixed users. Second, the protective effect may also be due to so called 
confounding by contra-indication, i.e., medications were less likely to be prescribed to 
suicidal patients. Third, having increased rate of suicidal behavior might indicate 
disorganized periods featured by poor adherence to medication treatment. Further research is 
needed to clarify whether stimulants indeed have a protective effect on suicidal behavior and 
if so, the mediating mechanisms of the protective effect. 
The findings from this study may inform clinical and public health decision-making. 
Moreover, within-individual comparisons deserve more attention in pharmacoepidemiologic 
research attempting to effectively control for time-constant factors within the same individual 
so as to minimize bias arising from confounding by indication. Additional research based on 
different designs and samples is needed to further elucidate the effects of stimulants and non-
stimulants on suicidal behavior, including the long-term effects. 
8.2 METHODOLOGICAL CONSIDERATIONS 
8.2.1 Measurement errors and misclassifications 
8.2.1.1 ADHD 
The ascertainment of ADHD cases in this thesis was predominantly based on ICD-10 
diagnosis given by psychiatric specialists and prescription of medication unique for ADHD 
treatment. The ICD-10 criteria for HDK are more conservative compared with the DSM-IV 
criteria for ADHD. In Sweden, pharmacotherapy is mainly preserved to patients with 
moderate to severe ADHD when non-pharmacological interventions alone have failed. Taken 
together, ADHD cases in this thesis tend to be individuals affected by more severe forms of 
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the disorder; thus, false negatives cannot be avoided, whereas bias due to false positives is 
unlikely. Although in a young cohort of Swedish twins, two approaches for the ascertainment 
of ADHD cases, diagnosis according to the NPR and assessment based parent-rated 
symptoms have shown considerable agreement,165 future validation studies on the ADHD 
diagnoses in the NPR are needed. 
Diagnostic criteria for adult ADHD were not available during the study period. The validity 
of ADHD diagnosis in adults used to be considered controversial.166,167 Nevertheless, prior 
studies have consistently reported that ADHD is a relatively stable condition that persists 
from childhood into adulthood in a substantial proportion of patients and is associated with 
impairment in both clinical and psychosocial functioning. The DSM-5 has added examples of 
symptom presentations in adulthood. In Sweden, the diagnostic assessments cover 
comprehensive aspects of intellectual impairment, autism, psychiatric and somatic 
comorbidities, and developmental history. Thus, we believe that ADHD diagnoses in adults 
in this thesis were valid from the perspective of research. 
8.2.1.2 Overweight and obesity 
Overweight and obesity were measured by BMI in Study II and III. BMI reflects statistical 
rather than physiological criteria for overweight and obesity. For instance, BMI might not be 
an optimal proxy for the synthesis and storage of cholesterol in adipose tissue. Individuals 
with the same BMI value may differ widely in their body composition. Central abdominal 
adiposity surrounding the viscera has been associated with increased risk of various adverse 
health outcomes.168 In contrast, peripheral adiposity in the gluteofemoral region appears to 
have protective effect against several chronic diseases.169 Therefore, BMI-measured 
overweight/obesity might not reflect the real harmful biological components in the process of 
cholesterol metabolism. 
In sibling-comparison studies, reliably measured exposure is crucial to avoid biased 
estimation due to random measurement errors. This will be further discussed in Section 8.2.3. 
8.2.1.3 Treatment status by medication 
The ascertainment of treatment period in Study IV was through a sequence of drug 
dispensations that might inaccurately reflect the actual consumption of medication by the 
patients due to non-adherence, i.e., the patients might not actually take the medications as 
prescribed. This might give rise to exposure time misclassification. The problem here is 
similar to the potential non-adherence to protocol in RCTs. The analyses in Study IV can be 
compared to intention-to-trait analyses (i.e., data for each participant were analysed according 
to the original treatment allocation) in most RCTs, which evaluate what would happen in real 
clinical settings if a treatment were offered.120 In Study IV, sensitivity analyses based on 
alternative definitions of on- and off-treatment periods did not invalidate the results from the 
main analyses, indicating that exposure time misclassification is unlikely to account for the 
non-significant results in within-individual analyses. 
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8.2.1.4 Suicide-related events 
Deaths from suicides have been validated via mortality statistics in Sweden,170,171 whereas 
suicide attempts retrieved from the NPR might be limited to relatively severe cases that were 
in need of medical care. Since the NPR might not capture mild forms of suicide attempts, the 
overall rate of suicide-related events might be underestimated, resulting in misclassification 
of outcome in Study IV. 
8.2.2 Estimates in familial co-aggregation studies 
In Study II, we first quantified the familial co-aggregation of ADHD and overweight/obesity 
in siblings and cousins, and subsequently tested the hypothesis that ADHD and 
overweight/obesity share etiological factors. In the crude models, ORs were used to describe 
the strength of the familial co-aggregation of ADHD and overweight/obesity in siblings and 
cousins. In the adjusted models, ORs significantly greater than 1 indicate an etiological 
overlap between ADHD and overweight/obesity. However, the magnitude of ORs cannot be 
directly translated into the extent to which the etiology of ADHD overlaps with the etiology 
of overweight/obesity, because ORs are relative measurements and the magnitude of ORs 
depends on the prevalence of each condition under study as well as the amount of familial 
factors jointly causing the coexistence of the two conditions in families. It is possible that 
familial co-aggregation studies of two highly prevalent conditions would yield relatively 
lower ORs compared with similar studies of two rare conditions. 
8.2.3 Assumptions in sibling comparison studies 
All research designs rely on a set of assumptions to provide valid inferences, with sibling-
comparison design being no exception. In Study III, the following assumptions must be met 
before a valid causal inference can be made. 
(1) Exposure and other covariates are reliably measured. 
Differentially exposed siblings differ in non-shared causes of exposure, including 
random measurement errors. Differentially exposed siblings are more vulnerable to 
misclassification of exposure due to random measurement errors 172 (e.g. maternal 
BMI value close to the cut-offs used for categorizing continuous BMI into normal 
weight, overweight, and obesity might give rise to misclassification between these 
categories in Study III). Such misclassification of exposure in Study III were most 
likely to be non-differential, which might serve as an alternative explanation for the 
attenuated associations in sibling-comparison analyses. 
 
(2) There is no sibling carryover or contagion effects. 
Sibling carryover or contagion effects occur when the exposure or outcome of one 
individual affects the exposure or outcome of his or her siblings.141 To test for 
carryover effects of maternal pre-pregnancy BMI in the first-born sibling on ADHD 
in the second-born sibling (i.e., asymmetric effects), we analyzed sibling pairs in 
subgroups divided by pattern of the variation in maternal BMI between pregnancies. 
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The stratified Cox regression analyses produced similar results irrespective of 
whether the exposed sibing was first-born or second-born, indicating that such 
asymmetric sibling carryover or contagion effects, if present, were of limited 
importance to the overall sibling-comparison analyses. 
 
(3) Differentially exposed siblings are representative for the general population. 
As within-family similariy in exposure increases, the number of differentially 
exposed siblings may dramatically decrease, which might threat the external validity 
of sibling-comparison studies.141 Therefore, it is crutial to check if differentially 
exposed siblings are representative for all siblings and if siblings differ in relevant 
aspects from individuals without siblings.173 In Study III, we analyzed siblings as 
unrelated individuals and compared the estimate with the population-level estimate. 
The similarity between the two estimates relieved us of the concern regarding external 
validity. 
When these assumptions are plausible, sibling-comparison studies may help scrutinize the 
role of unmeasured familial confounding in putative exposure-outcome associations and 
test competing causal hypotheses, even though they cannot prove causality. Causal 
inferences can be strengthened through convergent evidence from studies using different 
designs and samples and suffering from mutually exclusive limitations. 
8.2.4 Caveats of fixed effects models 
8.2.4.1 Unmeasured cluster-varying confounding 
Fixed effects models  (stratified Cox proportional hazards models in Study III and IV) cannot 
handle unmeasured confounding factors that vary within each cluster.174 In Study III, sibling-
comparison analyses cannot control for unmeasured confounding factors that were not shared 
by siblings. In Study IV, within-individual analyses cannot account for time-varying 
confounders occurring to each individual, such as sporadic onset of comorbid conditions 
associated with both medication treatment and suicide-related events. To address this issue, 
we restricted within-individual analysis in a subgroup of ADHD patients without major 
comorbid psychiatric conditions (i.e., mood disorder, conduct disorder, substance abuse 
disorder, and borderline personality disorder) and observed no increased rate of suicide-
related events associated with the use of ADHD medication. 
8.2.4.2 Non-informative clusters 
Fixed effects models cannot generate any effect estimates for variables that have no variation 
within clusters.174 In Study III, a family was non-informative (1) there was no within-family 
variation in any covariate in the model, including maternal pre-pregnancy BMI, or (2) all 
siblings in the family were free of ADHD. In Study IV, individuals without treatment switch 
or suicide-related event during the follow-up did not contribute information the within-
individual analyses. Non-informative clusters may result in loss of generalizability as 
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discussed in Section 8.2.3, and loss of precision, which can be reflected by wider confidence 
intervals and higher p-values. In Study III, we cannot exclude a causal effect of maternal pre-
pregnancy obesity on offspring ADHD given that the upper limit of the 95% CI for the HR 
was 1.56. Nevertheless, such causal effect, if existing, would not be as large as previously 
estimated. Likewise, an up to 30% increase in the rate of suicide-related events associated 
with the use of atomoxetine cannot be ruled out in Study IV, as the upper limit of the 95% CI 
for the HR was 1.30.  
8.2.4.3 Non-collapsibility 
When exposure-outcome associations are measured by ORs or HRs, adjusting for covariates 
that are associated with the outcome but independent of the exposure (i.e., non-confounders) 
may increase the regression coefficient for the exposure. This property of OR and HR is 
referred to as non-collapsibility. Fixed effects models automatically adjust for all factors that 
are constant within clusters regardless of whether they are true confounders; thus the models 
might be prone to the non-collapsibility effect. Non-collapsibility effect is not a bias, but it 
means that population-level estimates and cluster-specific estimates are derived from 
different statistical models and have different interpretations.175 In addition, non-collapsibility 
effect cannot alter the sign of the association and therefore is not responsible for the non-
significant findings in Study III and IV. 
8.2.5 Generalizability 
The studies involved in this thesis were based on nationwide Swedish samples with 
prospectively collected information over the past few decades. Nevertheless, lower incidence 
rate of ADHD diagnosis, lower average BMI value, and less prescriptions of ADHD 
medication in Sweden than in the United States indicate that the estimates in this thesis might 
be more transferable to the population in Sweden and other Nordic countries and less to 
countries with different social and cultural backgrounds and different levels of ethnic 
diversity. 
In Study II, due to lack of information on BMI for females at age 18-20, it is uncertain 
whether the findings can be generalized to female index persons and their relatives. However, 
results from Study III seem to support the findings from Study II, even though mothers and 
their offspring rather than siblings or cousins were investigated in Study III and maternal 
BMI was measured at childbearing age. Since BMI for male index persons was measured 
only once in young adulthood, the generalization of the results to other age groups should be 
made with caution. 
In Study III, we were aware of several threats to the representativeness of the exposure. First, 
mothers with varying BMI across pregnancies might not be representative for mothers with 
relatively stable BMI with respect to the biological mechanisms of overweight and obesity. It 
is possible that mothers who had obesity during two concessive pregnancies have more 
severe health related problems and their offspring were exposed to more adverse prenatal 
conditions. Second, mothers who had obesity during one pregnancy and managed to lose 
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weight during the subsequent pregnancy were likely to have better awareness of their health 
problems and their offspring might not be exposed to an extreme degree of detrimental 
prenatal environment. These issues were partly addressed by the same set of sensitivity 
analyses used for testing sibling carryover and contagion effects. These sensitivity analyses 
showed limited modifying effect by the pattern of maternal between-pregnancy variation in 
BMI. 
In Study IV, one issue to be aware of is whether individuals who discontinued their 
medication treatment were representative for individuals who adhered to the treatment 
throughout the entire follow-up. The data showed that a vast majority of study participants 
had both on- and off-treatment periods during the follow-up, which provided some evidence 
for an acceptable generalizability of the within-individual estimates based on individuals with 
intermittent treatment to the entire cohort of individuals with ADHD. 
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9 CONCLUSIONS 
This thesis has demonstrated how epidemiologic research using genetically informative 
designs has shifted the field from documenting putative associations to better understanding 
the underlying mechanisms for these associations. The main insights gained from the four 
studies are as follows: 
ADHD aggregates in families. The familial aggregation increases with increasing genetic 
relatedness. If family members are affected by ADHD that persists into adulthood, the 
familial aggregation can be particularly strong, suggesting that such families represent an 
important target group for diagnostic screening. 
ADHD and high BMI co-aggregate in families. Such familial co-aggregation of ADHD and 
high BMI can be at least in part attributed to common familial causes for the two conditions, 
indicating an etiological overlap between ADHD and high BMI. The etiological overlap can 
manifest as familial confounding, which plays a role in the empirical association between 
high maternal pre-pregnancy overweight/obesity and offspring ADHD at the population 
level. 
The population-level association between the use of ADHD medication and an increased risk 
of concomitant suicidal behavior is likely to be explained by the association between ADHD 
per se and suicidal behavior as well as other time-constant factors within the same individual. 
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10 FUTURE PERSPECTIVES 
Although the large familial aggregation study of ADHD in this thesis estimated the family 
risk of ADHD with relatively greater precision, accurate identification of the sources of the 
familial factors that cause the aggregation will still rely on quantitative genetic studies. 
Recently, in a Swedish population-based study of familial risk of autism, the researchers 
estimated the heritability of autism in an extended sibling sample and reported a heritability 
of approximately 50%, much lower than previously reported heritability estimates for 
autism.176 The heritability of ADHD has not yet been estimated in a similar setting. 
Joint use of quantitative measures of ADHD symptoms and clinical diagnosis of ADHD may 
help further elucidate whether there are sex-specific genetic and environmental influences on 
ADHD, even though such effects were not evident according to Study I. Longitudinal studies 
with even longer observation time are needed to confirm the influence of persistence of 
ADHD into adulthood on the familial aggregation of ADHD. Future family studies also need 
to estimate the familial risk of ADHD among inter-generation relatives such as parents and 
their offspring to complete the picture of the familial aggregation of the disorder. 
Bivariate quantitative genetic studies can be used to future elucidate the relative contributions 
of genetic and environmental influences on the covariance of ADHD and high BMI. 
Publically available summary statistics from the results of previous GWASs of ADHD and 
obesity can be used to estimate the genetic correlation between ADHD and obesity due to 
common genetic variants. ADHD and obesity polygenic scores can be generated based on 
these summary statistics, given genotype data from an independent sample. It would be 
interesting to look at whether joint use of the polygenic scores of these two traits can improve 
the performance of risk prediction of ADHD, for example, in the sample of the Child and 
Adolescent Twin Study in Sweden.177 
Although our findings did not support that high maternal pre-pregnancy BMI may cause 
offspring ADHD, this does not contradict obesity prevention among women at childbearing 
age. Pre-pregnancy obesity and weight gain have been associated with many prenatal and 
perinatal complications, including infant mortality, which is worth further investigation using 
elaborated measurements and different designs. In vitro fertilization (IVF) studies that once 
have helped reveal the contribution of familial confounding in the relationship between 
smoking during pregnancy and ADHD might also help unravel the nature of the relationship 
between maternal pre-pregnancy high BMI and offspring ADHD. As stated earlier, no single 
study can provide a definitive answer and the debate over whether high maternal pre-
pregnancy BMI may cause offspring ADHD has just begun and will likely continue. 
Due to the scarcity of suicide-related events in children, we failed to estimate the impact of 
ADHD medication on the risk of suicidal behavior solely in this age group. Future 
pharmacoepidemiologic research in younger patients, especially during initial phase of 
treatment and following dosage change, remains critical for ensuring the security of the 
pharmacotherapy of ADHD.   
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